Galectin Therapeutics Inc. (GALT) vs Upstream Bio, Inc. (UPB)
A side-by-side comparison of Galectin Therapeutics Inc. and Upstream Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GALT
Galectin Therapeutics Inc.
$3.76HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
UPB
Upstream Bio, Inc.
$4.59HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GALT vs UPB
growth of $100 · dividends reinvested · last 2yGALT +37.1% (+17.1%/yr)UPB -78.0% (-53.0%/yr)GALT compounded faster over this window
Log scale — wide-divergence pair
GALT UPB
GALT vs UPB: by the numbers
- •UPB is the larger company ($250M vs $248M market cap).
- •Both run net losses; GALT's is the smaller (0.00% vs -4955.67% net margin).
Metrics side by side
Valuation
| Metric | GALT | UPB |
|---|---|---|
| P/S ratio | N/A | 79.10 |
| P/B ratio | N/A | 0.92 |
Profitability
| Metric | GALT | UPB |
|---|---|---|
| Gross margin | 0.00% | 98.45% |
| Operating margin | 0.00% | -5618.82% |
| Net margin | 0.00% | -4955.67% |
| ROE | N/A | -57.76% |
| ROIC | -1718.59% | -62.51% |
Growth (annualized)
| Metric | GALT | UPB |
|---|---|---|
| Total return CAGR (5Y) | 0.60% | N/A |
Go deeper
Dig into the metrics
Galectin Therapeutics ROEUpstream Bio ROEGalectin Therapeutics operating marginUpstream Bio operating marginGalectin Therapeutics revenue growthUpstream Bio revenue growthGalectin Therapeutics free cash flowUpstream Bio free cash flow
Galectin Therapeutics & Upstream Bio appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.